サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1625468

難治性痛風の市場規模、シェア、動向、産業分析レポート：治療タイプ別、流通チャネル別、地域別 - 市場予測、2025年～2034年

Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, Distribution Channel, and Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 117 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
難治性痛風の市場規模、シェア、動向、産業分析レポート：治療タイプ別、流通チャネル別、地域別 - 市場予測、2025年～2034年
出版日: 2024年12月01日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の難治性痛風市場規模は2034年までに15億9,924万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

難治性痛風市場は、従来の治療法に反応しない重症痛風症例の増加により、着実に拡大しています。難治性痛風は、標準治療にもかかわらず症状が持続することを特徴とし、高度な治療アプローチが必要とされ、市場成長に大きく寄与しています。市場は生物学的治療と非生物学的治療に区分され、生物学的治療はその標的作用と複雑な症例の管理における高い有効性により注目すべき市場シェアを獲得しています。モノクローナル抗体や酵素阻害剤を含むこれらの治療は、ますます支持されるようになっており、市場の需要を押し上げ、市場の拡大を促進しています。

革新的な治療オプションの利用可能性に関するヘルスケア専門家や患者の意識の高まりも、市場規模を押し上げる重要な要因です。難治性痛風の主要な治療機関である病院や専門クリニックは、高度な治療や専門家による治療を受けることができるため、市場成長において極めて重要な役割を果たしています。この分野は、生物学的製剤の採用増加や専門施設の利用可能性に支えられ、大きな成長が見込まれています。

技術の進歩、進行中の研究開発、新薬の承認が難治性痛風市場をさらに強化しています。さらに、重症痛風に罹患しやすい老年人口の増加が市場需要の増加に寄与しています。先進治療へのアクセスを改善することを目的とした政府の好意的な取り組みやヘルスケア政策も市場拡大を支えています。

難治性痛風市場レポートハイライト

治療タイプ別では、生物学的製剤が幅広い適用範囲と症状管理における有効性により、難治性痛風市場で大きな市場シェアを占めています。

流通チャネル別では、重症かつ複雑な症例に対応できる病院および専門クリニックが、予測期間中に大きな成長を遂げると予測されます。

北米は高度なヘルスケアインフラを有し、痛風の有病率が高いことから、難治性痛風市場で最大のシェアを占めています。

アジア太平洋地域は、新興国におけるヘルスケア投資の増加と痛風管理に対する意識の高まりにより、予測期間中に大きな成長が見込まれます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の難治性痛風市場の洞察

  • 市場スナップショット
  • 難治性痛風市場力学
    • 促進要因と機会
      • 難治性痛風治療における生物学的製剤の需要増加
      • 個別化医療と遺伝子検査への注目が高まる
    • 抑制要因と課題
      • 高額な治療費
  • PESTEL分析
  • 難治性痛風市場のアプリケーション動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界の難治性痛風市場：治療タイプ別

  • 主な調査結果
  • イントロダクション
  • 生物学的治療
  • 非生物学的治療

第6章 世界の難治性痛風市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院および専門クリニック
  • 小売薬局
  • オンライン薬局

第7章 世界の難治性痛風市場：地域別

  • 主な調査結果
  • イントロダクション
    • 難治性痛風市場評価：地域、2020～2034年
  • 北米
    • 北米：治療タイプ別、2020～2034年
    • 北米：流通チャネル別、2020～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：治療タイプ別、2020～2034年
    • 欧州：流通チャネル別、2020～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋地域：治療タイプ別、2020～2034年
    • アジア太平洋地域：流通チャネル別、2020～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ
    • 中東・アフリカ：治療タイプ別、2020～2034年
    • 中東・アフリカ：流通チャネル別、2020～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ
  • ラテンアメリカ
    • ラテンアメリカ：治療タイプ別、2020～2034年
    • ラテンアメリカ：流通チャネル別、2020～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Horizon Therapeutics
  • Novartis AG
  • Takeda Pharmaceuticals
  • Grifols, S.A.
  • Ironwood Pharmaceuticals
  • Selecta Biosciences
  • Teijin Pharma
  • Pfizer Inc.
  • Sobi（Swedish Orphan Biovitrum）
  • LG Chem
  • AstraZeneca
  • Mylan N.V.
  • Sanofi
  • GlaxoSmithKline plc（GSK）
  • Ardea Biosciences
図表

List of Tables:

Table 1 Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 2 Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 3 North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 4 North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 5 US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 6 US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 7 Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 8 Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 9 Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 10 Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 11 UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 12 UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 13 France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 14 France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 15 Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 16 Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 17 Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 18 Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 19 Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 20 Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 21 Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 22 Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 23 Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 24 Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 25 Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 26 Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 27 Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 28 Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 29 China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 30 China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 31 India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 32 India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 33 Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 34 Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 35 Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 36 Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 37 Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 38 Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 39 South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 40 South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 41 Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 42 Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 43 Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 44 Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 45 Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 46 Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 47 Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 48 Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 49 UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 50 UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 51 Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 52 Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 53 South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 54 South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 55 Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 56 Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 57 Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 58 Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 59 Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 60 Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 61 Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 62 Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 63 Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 64 Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

Table 65 Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)

Table 66 Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

List of Figures:

Figure 1. Global Refractory Gout Market, 2020-2034 (USD Million)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Price

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Treatment Type

Figure 7. Global Refractory Gout Market, by Treatment Type, 2024 & 2034 (USD Million)

Figure 8. Market by Distribution Channel

Figure 9. Global Refractory Gout Market, by Distribution Channel, 2024 & 2034 (USD Million)

目次
Product Code: PM5327

The global refractory gout market size is expected to reach USD 1,599.24 million by 2034, according to a new study by Polaris Market Research. The report "Refractory Gout Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Biological and Non-Biological Treatments), Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The refractory gout market is witnessing steady expansion, driven by the increasing prevalence of severe gout cases unresponsive to conventional therapies. Refractory gout, characterized by persistent symptoms despite standard treatment, requires advanced therapeutic approaches, which significantly contribute to market growth. The market is segmented into biological and non-biological treatments, with biological therapies gaining notable market share due to their targeted action and higher efficacy in managing complex cases. These treatments, which include monoclonal antibodies and enzyme inhibitors, are increasingly favored, boosting market demand and fostering market expansion.

The rising awareness among healthcare professionals and patients about the availability of innovative treatment options is another crucial factor driving market size. Hospitals and specialty clinics, as primary treatment providers for refractory gout, play a pivotal role in market growth by offering access to advanced therapies and expert care. This segment is expected to witness significant growth, supported by the increasing adoption of biologics and the availability of specialized facilities.

Technological advancements, ongoing research and development, and the approval of novel drugs are further enhancing the refractory gout market. Additionally, the growing geriatric population, which is more susceptible to severe gout, is contributing to the increasing market demand. Favorable government initiatives and healthcare policies aimed at improving access to advanced treatments also support market expansion.

Refractory Gout Market Report Highlights:

In terms of treatment type, the biological treatment segment holds the significant market share in the refractory gout market due to their broad application and efficacy in managing symptoms.

By distribution channel, the hospitals and specialty clinics segment is expected to witness significant growth over the forecast period, driven by their capacity to handle severe and complex cases.

North America holds the largest share of the refractory gout market, with its advanced healthcare infrastructure and high prevalence of gout.

Asia Pacific is expected to witness significant growth over the forecast period, owing to increasing healthcare investments and rising awareness of gout management in emerging economies.

Polaris Market Research has segmented the refractory gout market report on the basis of treatment type, distribution channel, and region:

By Treatment Type Outlook (Revenue USD Million, 2020-2034)

  • Biologics
  • Pegloticase (Krystexxa)
  • Canakinumab
  • Non-Biologics
  • NSAIDs
  • Corticosteroids
  • Colchicine
  • Uricosurics (e.g., probenecid)

By Distribution Channel Outlook (Revenue USD Million, 2020-2034)

  • Hospitals and Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

By Regional Outlook (Revenue USD Million, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Refractory Gout Market Insights

  • 4.1. Refractory Gout Market - Market Snapshot
  • 4.2. Refractory Gout Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Demand for Biologics in Refractory Gout Treatment
      • 4.2.1.2. Surging Focus on Personalized Medicine and Genetic Testing
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Treatment Costs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Refractory Gout Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Refractory Gout Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
  • 5.3. Biologics
    • 5.3.1. Global Refractory Gout Market, by Biologics, by Region, 2020-2034 (USD Million)
    • 5.3.2. Pegloticase (Krystexxa)
      • 5.3.2.1. Global Refractory Gout Market, by Pegloticase (Krystexxa), by Region, 2020-2034 (USD Million)
    • 5.3.3. Canakinumab
      • 5.3.3.1. Global Refractory Gout Market, by Canakinumab, by Region, 2020-2034 (USD Million)
  • 5.4. Non-Biologics
    • 5.4.1. Global Refractory Gout Market, by Non-Biologics, by Region, 2020-2034 (USD Million)
    • 5.4.2. NSAIDs
      • 5.4.2.1. Global Refractory Gout Market, by NSAIDs, by Region, 2020-2034 (USD Million)
    • 5.4.3. Corticosteroids
      • 5.4.3.1. Global Refractory Gout Market, by Corticosteroids, by Region, 2020-2034 (USD Million)
    • 5.4.4. Colchicine
      • 5.4.4.1. Global Refractory Gout Market, by Colchicine, by Region, 2020-2034 (USD Million)
    • 5.4.5. Uricosurics (e.g., probenecid)
      • 5.4.5.1. Global Refractory Gout Market, by Uricosurics (e.g., probenecid), by Region, 2020-2034 (USD Million)

6. Global Refractory Gout Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 6.3. Hospitals and Specialty Clinics
    • 6.3.1. Global Refractory Gout Market, by Hospitals and Specialty Clinics, by Region, 2020-2034 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Refractory Gout Market, by Retail Pharmacies, by Region, 2020-2034 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Refractory Gout Market, by Online Pharmacies, by Region, 2020-2034 (USD Million)

7. Global Refractory Gout Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Refractory Gout Market Assessment, By Geography, 2020-2034 (USD Million)
  • 7.3. Refractory Gout Market - North America
    • 7.3.1. North America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.3.2. North America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.3. Refractory Gout Market - US
      • 7.3.3.1. US: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.3.2. US: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.3.4. Refractory Gout Market - Canada
      • 7.3.4.1. Canada: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.3.4.2. Canada: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.4. Refractory Gout Market - Europe
    • 7.4.1. Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.4.2. Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.3. Refractory Gout Market - UK
      • 7.4.3.1. UK: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.3.2. UK: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.4. Refractory Gout Market - France
      • 7.4.4.1. France: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.4.2. France: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.5. Refractory Gout Market - Germany
      • 7.4.5.1. Germany: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.5.2. Germany: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.6. Refractory Gout Market - Italy
      • 7.4.6.1. Italy: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.6.2. Italy: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.7. Refractory Gout Market - Spain
      • 7.4.7.1. Spain: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.7.2. Spain: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.8. Refractory Gout Market - Netherlands
      • 7.4.8.1. Netherlands: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.8.2. Netherlands: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.9. Refractory Gout Market - Russia
      • 7.4.9.1. Russia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.9.2. Russia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.4.10. Refractory Gout Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.4.10.2. Rest of Europe: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.5. Refractory Gout Market - Asia Pacific
    • 7.5.1. Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.5.2. Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.3. Refractory Gout Market - China
      • 7.5.3.1. China: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.3.2. China: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.4. Refractory Gout Market - India
      • 7.5.4.1. India: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.4.2. India: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.5. Refractory Gout Market - Malaysia
      • 7.5.5.1. Malaysia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.5.2. Malaysia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.6. Refractory Gout Market - Japan
      • 7.5.6.1. Japan: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.6.2. Japan: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.7. Refractory Gout Market - Indonesia
      • 7.5.7.1. Indonesia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.7.2. Indonesia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.8. Refractory Gout Market - South Korea
      • 7.5.8.1. South Korea: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.8.2. South Korea: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.9. Refractory Gout Market - Australia
      • 7.5.9.1. Australia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.9.2. Australia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.5.10. Refractory Gout Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.5.10.2. Rest of Asia Pacific: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.6. Refractory Gout Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.6.2. Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.3. Refractory Gout Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.3.2. Saudi Arabia: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.4. Refractory Gout Market - UAE
      • 7.6.4.1. UAE: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.4.2. UAE: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.5. Refractory Gout Market - Israel
      • 7.6.5.1. Israel: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.5.2. Israel: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.6. Refractory Gout Market - South Africa
      • 7.6.6.1. South Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.6.2. South Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.6.7. Refractory Gout Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.6.7.2. Rest of Middle East & Africa: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
  • 7.7. Refractory Gout Market - Latin America
    • 7.7.1. Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
    • 7.7.2. Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.3. Refractory Gout Market - Mexico
      • 7.7.3.1. Mexico: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.3.2. Mexico: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.4. Refractory Gout Market - Brazil
      • 7.7.4.1. Brazil: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.4.2. Brazil: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.5. Refractory Gout Market - Argentina
      • 7.7.5.1. Argentina: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.5.2. Argentina: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)
    • 7.7.6. Refractory Gout Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Refractory Gout Market, by Treatment Type, 2020-2034 (USD Million)
      • 7.7.6.2. Rest of Latin America: Refractory Gout Market, by Distribution Channel, 2020-2034 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Horizon Therapeutics
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Takeda Pharmaceuticals
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols, S.A.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Ironwood Pharmaceuticals
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Selecta Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Teijin Pharma
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Pfizer Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Sobi (Swedish Orphan Biovitrum)
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. LG Chem
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. AstraZeneca
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. Mylan N.V.
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Sanofi
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. GlaxoSmithKline plc (GSK)
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Ardea Biosciences
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development